葡萄糖依赖性促胰岛素多肽（GIP）。

IF 7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Molecular Metabolism Pub Date : 2025-02-28 DOI:10.1016/j.molmet.2025.102118

Timo D. Müller , Alice Adriaenssens , Bo Ahrén , Matthias Blüher , Andreas L. Birkenfeld , Jonathan E. Campbell , Matthew P. Coghlan , David D'Alessio , Carolyn F. Deacon , Stefano DelPrato , Jonathan D. Douros , Daniel J. Drucker , Natalie S. Figueredo Burgos , Peter R. Flatt , Brian Finan , Ruth E. Gimeno , Fiona M. Gribble , Matthew R. Hayes , Christian Hölscher , Jens J. Holst , Matthias H. Tschöp

{"title":"葡萄糖依赖性促胰岛素多肽（GIP）。","authors":"Timo D. Müller , Alice Adriaenssens , Bo Ahrén , Matthias Blüher , Andreas L. Birkenfeld , Jonathan E. Campbell , Matthew P. Coghlan , David D'Alessio , Carolyn F. Deacon , Stefano DelPrato , Jonathan D. Douros , Daniel J. Drucker , Natalie S. Figueredo Burgos , Peter R. Flatt , Brian Finan , Ruth E. Gimeno , Fiona M. Gribble , Matthew R. Hayes , Christian Hölscher , Jens J. Holst , Matthias H. Tschöp","doi":"10.1016/j.molmet.2025.102118","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been developed as a therapeutic and thus has been overshadowed by the other incretin, glucagon-like peptide 1 (GLP-1), which is the basis for several successful drugs to treat diabetes and obesity. However, there has been a rekindling of interest in GIP biology in recent years, in great part due to pharmacology demonstrating that both GIPR agonism and antagonism may be beneficial in treating obesity and diabetes. This apparent paradox has reinvigorated the field, led to new lines of investigation, and deeper understanding of GIP.</div></div><div><h3>Scope of Review</h3><div>In this review, we provide a detailed overview on the multifaceted nature of GIP biology and discuss the therapeutic implications of GIPR signal modification on various diseases.</div></div><div><h3>Major Conclusions</h3><div>Following its classification as an incretin hormone, GIP has emerged as a pleiotropic hormone with a variety of metabolic effects outside the endocrine pancreas. The numerous beneficial effects of GIPR signal modification render the peptide an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, drug-induced nausea and both bone and neurodegenerative disorders.</div></div>","PeriodicalId":18765,"journal":{"name":"Molecular Metabolism","volume":"95 ","pages":"Article 102118"},"PeriodicalIF":7.0000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Glucose-dependent insulinotropic polypeptide (GIP)\",\"authors\":\"Timo D. Müller , Alice Adriaenssens , Bo Ahrén , Matthias Blüher , Andreas L. Birkenfeld , Jonathan E. Campbell , Matthew P. Coghlan , David D'Alessio , Carolyn F. Deacon , Stefano DelPrato , Jonathan D. Douros , Daniel J. Drucker , Natalie S. Figueredo Burgos , Peter R. Flatt , Brian Finan , Ruth E. Gimeno , Fiona M. Gribble , Matthew R. Hayes , Christian Hölscher , Jens J. Holst , Matthias H. Tschöp\",\"doi\":\"10.1016/j.molmet.2025.102118\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been developed as a therapeutic and thus has been overshadowed by the other incretin, glucagon-like peptide 1 (GLP-1), which is the basis for several successful drugs to treat diabetes and obesity. However, there has been a rekindling of interest in GIP biology in recent years, in great part due to pharmacology demonstrating that both GIPR agonism and antagonism may be beneficial in treating obesity and diabetes. This apparent paradox has reinvigorated the field, led to new lines of investigation, and deeper understanding of GIP.</div></div><div><h3>Scope of Review</h3><div>In this review, we provide a detailed overview on the multifaceted nature of GIP biology and discuss the therapeutic implications of GIPR signal modification on various diseases.</div></div><div><h3>Major Conclusions</h3><div>Following its classification as an incretin hormone, GIP has emerged as a pleiotropic hormone with a variety of metabolic effects outside the endocrine pancreas. The numerous beneficial effects of GIPR signal modification render the peptide an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, drug-induced nausea and both bone and neurodegenerative disorders.</div></div>\",\"PeriodicalId\":18765,\"journal\":{\"name\":\"Molecular Metabolism\",\"volume\":\"95 \",\"pages\":\"Article 102118\"},\"PeriodicalIF\":7.0000,\"publicationDate\":\"2025-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212877825000250\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212877825000250","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

背景：葡萄糖依赖性胰岛素多肽（GIP）是第一个被发现的肠促胰岛素，在维持健康人的葡萄糖耐量中起着重要作用。直到最近，GIP还没有作为一种治疗药物被开发出来，因此被另一种肠促胰岛素，胰高血糖素样肽1 （GLP-1）所掩盖，GLP-1是几种成功治疗糖尿病和肥胖的药物的基础。然而，近年来对GIP生物学的兴趣重新燃起，这在很大程度上是由于药理学表明，GIPR的激动作用和拮抗作用可能对治疗肥胖和糖尿病有益。这个明显的悖论使这个领域重新焕发了活力，导致了新的研究方向，并加深了对GIP的理解。在这篇综述中，我们详细概述了GIP生物学的多面性，并讨论了GIPR信号修饰在各种疾病中的治疗意义。主要结论：继被归类为肠促胰岛素后，GIP已成为一种多效激素，在内分泌胰腺外具有多种代谢作用。GIPR信号修饰的许多有益作用使该肽成为治疗肥胖、糖尿病、药物性恶心以及骨和神经退行性疾病的药物治疗的有趣候选者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Glucose-dependent insulinotropic polypeptide (GIP)

Background

Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been developed as a therapeutic and thus has been overshadowed by the other incretin, glucagon-like peptide 1 (GLP-1), which is the basis for several successful drugs to treat diabetes and obesity. However, there has been a rekindling of interest in GIP biology in recent years, in great part due to pharmacology demonstrating that both GIPR agonism and antagonism may be beneficial in treating obesity and diabetes. This apparent paradox has reinvigorated the field, led to new lines of investigation, and deeper understanding of GIP.

Scope of Review

In this review, we provide a detailed overview on the multifaceted nature of GIP biology and discuss the therapeutic implications of GIPR signal modification on various diseases.

Major Conclusions

Following its classification as an incretin hormone, GIP has emerged as a pleiotropic hormone with a variety of metabolic effects outside the endocrine pancreas. The numerous beneficial effects of GIPR signal modification render the peptide an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, drug-induced nausea and both bone and neurodegenerative disorders.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Molecular Metabolism ENDOCRINOLOGY & METABOLISM-

CiteScore

14.50

自引率

2.50%

发文量

219

审稿时长

43 days

期刊介绍： Molecular Metabolism is a leading journal dedicated to sharing groundbreaking discoveries in the field of energy homeostasis and the underlying factors of metabolic disorders. These disorders include obesity, diabetes, cardiovascular disease, and cancer. Our journal focuses on publishing research driven by hypotheses and conducted to the highest standards, aiming to provide a mechanistic understanding of energy homeostasis-related behavior, physiology, and dysfunction. We promote interdisciplinary science, covering a broad range of approaches from molecules to humans throughout the lifespan. Our goal is to contribute to transformative research in metabolism, which has the potential to revolutionize the field. By enabling progress in the prognosis, prevention, and ultimately the cure of metabolic disorders and their long-term complications, our journal seeks to better the future of health and well-being.